Xencor マネジメント

マネジメント基準チェック /24

Xencorの CEO はBassil Dahiyatで、 Aug1997年に任命され、の在任期間は 27.25年です。の年間総報酬は$ 7.97Mで、 8.8%給与と91.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.35%を直接所有しており、その価値は€ 5.40M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と7.6年です。

主要情報

Bassil Dahiyat

最高経営責任者

US$8.0m

報酬総額

CEO給与比率	8.8%
CEO在任期間	27.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	2.8yrs
取締役会の平均在任期間	7.6yrs

経営陣の近況

Recent updates

CEO報酬分析

Xencor の収益と比較して、Bassil Dahiyat の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$198m
Jun 30 2024	n/a	n/a	-US$177m
Mar 31 2024	n/a	n/a	-US$133m
Dec 31 2023	US$8m	US$700k	-US$126m
Sep 30 2023	n/a	n/a	-US$119m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$140m
Dec 31 2022	US$8m	US$670k	-US$55m
Sep 30 2022	n/a	n/a	US$30m
Jun 30 2022	n/a	n/a	US$22m
Mar 31 2022	n/a	n/a	US$109m
Dec 31 2021	US$5m	US$625k	US$83m
Sep 30 2021	n/a	n/a	-US$4m
Jun 30 2021	n/a	n/a	US$24m
Mar 31 2021	n/a	n/a	-US$64m
Dec 31 2020	US$4m	US$600k	-US$69m
Sep 30 2020	n/a	n/a	-US$83m
Jun 30 2020	n/a	n/a	-US$80m
Mar 31 2020	n/a	n/a	-US$61m
Dec 31 2019	US$4m	US$567k	US$27m
Sep 30 2019	n/a	n/a	US$36m
Jun 30 2019	n/a	n/a	US$49m
Mar 31 2019	n/a	n/a	US$39m
Dec 31 2018	US$4m	US$550k	-US$70m
Sep 30 2018	n/a	n/a	-US$45m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$525k	-US$38m

報酬と市場: Bassilの総報酬 ($USD 7.97M ) は、 German市場 ($USD 1.61M ) の同規模の企業の平均を上回っています。

報酬と収益: Bassilの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Bassil Dahiyat (54 yo)

27.3yrs

在職期間

US$7,965,955

報酬

Dr. Bassil I. Dahiyat, Ph D., Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat serves as an Independent Director at Terray Ther...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Bassil Dahiyat	Co-Founder	27.3yrs	US$7.97m	0.35% € 5.4m
John Desjarlais	Executive VP of Research & Chief Scientific Officer	10.3yrs	US$3.21m	0.24% € 3.7m
Celia Eckert	Senior VP	5.2yrs	US$2.02m	0.027% € 410.7k
Nancy Valente	Executive VP & Chief Development Officer	1.5yrs	US$5.35m	0.013% € 203.5k
Bart Cornelissen	Senior VP & CFO	less than a year	データなし	データなし
Charles Liles	Associate Director and Head of Corporate Communications & Investor Relations	no data	データなし	データなし
Jennifer Sandoz	Senior VIce President of Human Resources	3.3yrs	データなし	データなし
Jeremy Grunstein	Senior Vice President of Business Development	2.8yrs	データなし	データなし
Kirk Rosemark	Senior Vice President of Regulatory Affairs & Quality Assurance	2.8yrs	データなし	データなし
Eric Kowack	Senior Vice President of Program Leadership & Alliance Management	1.8yrs	データなし	データなし
Dane Leone	Senior VP of Corporate Strategy	less than a year	データなし	データなし

2.8yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: XE9の経営陣は経験豊富であると考えられます ( 2.8年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Bassil Dahiyat	Co-Founder	27.3yrs	US$7.97m	0.35% € 5.4m
Richard Ranieri	Independent Director	6.9yrs	US$347.02k	0.0036% € 54.9k
Alan Montgomery	lead Independent Director	9.7yrs	US$384.19k	0.013% € 200.3k
Kevin Gorman	Independent Director	7.6yrs	US$342.50k	0.0034% € 52.8k
Jeffrey Ravetch	Member of Scientific Advisory Board	15.4yrs	データなし	データなし
Ellen Feigal	Independent Director	6yrs	US$348.00k	0.012% € 186.0k
Kurt Gustafson	Independent Director	10.3yrs	US$346.50k	0.0050% € 76.8k
Dagmar Rosa-Bjorkeson	Independent Director	4.9yrs	US$346.25k	0% € 0
Barbara Klencke	Independent Director	1.2yrs	US$467.35k	データなし

7.6yrs

平均在職期間

67yo

平均年齢

経験豊富なボード: XE9の取締役会は経験豊富であると考えられます ( 7.6年の平均在任期間)。

Xencor マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Recent updates

Now 22% overvalued after recent price rise

Third quarter 2024 earnings released: US$0.70 loss per share (vs US$0.40 loss in 3Q 2023)

Xencor, Inc. Doses First Subject in Phase 1/2 Study of XmAb®?942 in Development for Patients with Inflammatory Bowel Disease

Now 22% overvalued after recent price rise

Xencor Announces Dagmar Rosa-Bjorkeson Not Stand for Re-Election as Director

Now 24% overvalued after recent price rise

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Xencor, Inc. has completed a Follow-on Equity Offering in the amount of $175.001111 million.

Now 28% undervalued after recent price drop

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$1.07 loss per share (vs US$0.37 loss in 2Q 2023)

First quarter 2024 earnings released: US$1.11 loss per share (vs US$1.02 loss in 1Q 2023)

New minor risk - Shareholder dilution

Xencor Appoints Bart Cornelissen as Senior Vice President

Co-Founder recently sold €270k worth of stock

New minor risk - Profitability

Full year 2023 earnings released: US$2.08 loss per share (vs US$0.93 loss in FY 2022)

Xencor, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Xencor, Inc. Appoints Dane Leone as Senior Vice President, Corporate Strategy

Third quarter 2023 earnings released: US$0.40 loss per share (vs US$0.55 loss in 3Q 2022)

Xencor, Inc. to Report Q3, 2023 Results on Nov 07, 2023

John J. Kuch to Retire as Chief Financial Officer of Xencor, Inc. in March 2024

Xencor Announces Planned Retirement of Senior Vice President John Kuch

Xencor, Inc. Appoints Barbara J. Klencke to Board of Directors

Second quarter 2023 earnings released: US$0.37 loss per share (vs US$0.57 loss in 2Q 2022)

Xencor, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Xencor, Inc. Presents Clinical Results from Phase 1a Study of XmAb®564 at the EULAR 2023 Congress

Insufficient new directors

First quarter 2023 earnings released: US$1.02 loss per share (vs US$0.40 profit in 1Q 2022)

Co-Founder recently sold €172k worth of stock

Full year 2022 earnings released: US$0.93 loss per share (vs US$1.42 profit in FY 2021)

Xencor, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Senior VP & Chief Medical Officer recently sold €95k worth of stock

Xencor, Inc. Presents Data from Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin Lymphoma At the American Society of Hematology Annual Meeting

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$0.69 loss in 3Q 2021)

Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study

Xencor, Inc. to Report Q3, 2022 Results on Nov 07, 2022

High number of new directors

Xencor, Inc. to Present Seven Posters on Multiple Clinical Trials and Research-Stage Programs At the SITC Annual Meeting

High number of new directors

Xencbor, Inc. Announces the Appointment of Nancy Valente to Its Board of Directors

Second quarter 2022 earnings released: US$0.57 loss per share (vs US$0.90 profit in 2Q 2021)

Xencor, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Investor sentiment improved over the past week

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 2000 Growth-Defensive Index

Investor sentiment improved over the past week

Xencor, Inc. Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors

First quarter 2022 earnings released: EPS: US$0.40 (vs US$0.043 loss in 1Q 2021)

Co-Founder recently sold €65k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Xencor, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting

Zenas BioPharma Limited acquired Exclusive worldwide rights to Obexelimab from Xencor, Inc. (NasdaqGM:XNCR).

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.22 loss in 3Q 2020)

Director Yujiro Hata has joined 3rd company board

Second quarter 2021 earnings released: EPS US$0.90 (vs US$0.61 loss in 2Q 2020)

Xencor, Inc.(NasdaqGM:XNCR) dropped from Russell 3000E Value Index

Sotrovimab Receives U.S. FDA Emergency Use Authorization for the Treatment of COVID-19

First quarter 2021 earnings released: US$0.043 loss per share (vs US$0.14 loss in 1Q 2020)

Xencor, Inc. Doses First Subject in Phase 1 Study of XMAB®564, an Engineered IL-2 Cytokine in Development for Autoimmune Diseases

Co-Founder recently sold €106k worth of stock

Xencor and UCLA Enter Collaboration to Discover and Develop Novel XmAb® Therapeutics

Full year 2020 earnings released: US$1.21 loss per share (vs US$0.47 profit in FY 2019)

Revenue beats expectations

Xencor, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €42.20

Xencor, Inc. and The University of Texas MD Anderson Cancer Center Enter Strategic Collaboration to Develop Novel T Cell-Engaging Bispecific Antibodies for Potential Treatment of Patients with Cancer

New 90-day high: €38.20

Senior VP & Chief Medical Officer recently sold €135k worth of stock

マネジメント基準チェック /24